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Background: Dipyrithione (PTS2) is widely used as a bactericide and fungicide. Here, we investigated whether PTS2
has broad-spectrum antitumor activity by studying its cytotoxicity and proapoptotic effects in four cancer cell lines.
Methods: We used MTT assays and trypan blue staining to test the viability of cancer cell lines. Hoechst 33258 and
DAPI staining were used to observe cell apoptosis. Cell-cycle percentages were analyzed by flow cytometry.
Apoptosis was assayed using caspase-3 and poly (ADP-ribose) polymerase (PARP) combined with Western blotting.
Student’s t-test was used for statistical analysis.
Results: PTS2 inhibited proliferation in four cancer cell lines in a dose-dependent manner. Treated cells showed
shrinkage, irregular fragments, condensed and dispersed blue fluorescent particles compared with control cells.
PTS2 induced cycle-arrest and death. Cleavage of caspase-9, caspase-3, and PARP were detected in PTS2-treated
cells. Antitumor activity of PTS2 was more effective against widely used cancer drugs and its precursor.
Conclusions: PTS2 appears to have novel cytotoxicity and potent broad-spectrum antitumor activity, which
suggests its potential as the basis of an anticancer drug.
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Apoptosis is a cellular progression characterized by a series
of tightly regulated molecular processes leading to cell
death [1]. There are two independent apoptosis pathways:
the death receptor pathway and the mitochondria pathway
[2], both of which converge on a family of cysteine
aspartases called caspases, whose activity drives the bio-
chemical events leading to cellular disassembly and death.
Novel second mitochondria-derived activator of caspases
(Smac) mimetic compounds sensitize human leukemia cell
lines to conventional chemotherapies that induce death
receptor-mediated apoptosis [3,4]. During apoptosis, cyto-
chrome c, a component of the mitochondrial electron* Correspondence: xlduan0311@163.com; yinzhimin@njnu.edu.cn
1The Key Lab of Animal Physiology, College of Life Science, Hebei Normal
University, Hebei Province, Shijiazhuang 050024, China
3Jiangsu Province Key Laboratory of Molecular and Medical Biotechnology,
College of Life Science, Nanjing Normal University, Nanjing 210046, China
Full list of author information is available at the end of the article
© 2013 Fan et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortransfer chain, releases from mitochondria to the cytosol,
and binds to Apaf-1, a cytosolic protein, forming the Apaf-
1/cytochrome c complex, which then oligomerizes and
forms apoptosomes by recruiting multiple procaspase-9
molecules, and then cleaving and activating downstream
apoptosis effectors such as caspase-3, and PARP [5]. As
malignancies grow, cancer cells evolve around mechanisms
that limit cell proliferation, such as apoptosis and replica-
tive senescence. Successful cancer therapies may trigger
tumor-selective apoptosis [6].
Pyrithione (2-pyridinethiol-1-oxide, PT) has been used
as a bactericide and fungicide for more than 50 years [7].
PT derivatives, such as zinc PT and sodium PT, are widely
used as cosmetic preservatives and as anti-dandruff agents
in shampoos. Zinc PT can reportedly induce apoptosis be-
cause of its role as a zinc-ionophore [8,9]. Compounds
containing -SH group are quickly oxidized to generate
disulfide. For PT, such self-oxidation would result in the
formation of the dimer, 2,2’-dithiobispyridine-1,1’-dioxide. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bacterial and anti-fungal activity. Our previous study dem-
onstrated the cytotoxicity and effect of PTS2 in HeLa cells
[4], and PTS2 inhibited inflammatory responses induced
by lipopolysaccharides (LPS) in RAW264.7 cells, thus
protecting mice against endotoxic shock by exerting anti-
inflammatory effects through decreased formation of
chemokine IP-10/CXCL10 and reduced acute oleic acid-
induced lung injury [10-12].
Here we reported novel toxicity, including inhibited pro-
liferation and induced apoptosis, of PTS2 in four cancer
cell lines. Our results indicated that PTS2 has broad-
spectrum antitumor activity, suggesting its potential as the
basis of an anticancer drug.
Methods
Cell culture
MDA-MB-231 (human breast cancer cell line), KB (naso-
pharyngeal carcinoma cell line), U937 (human monoblast
leukemia cell line), and K562 (human leukemia cell line)
were purchased from the CBCAS (Cell Bank of the Chinese
Academic of Sciences, Shanghai, China). Cells were
maintained in RPMI1640 (GIBCO), supplemented with
10% (v/v) fetal bovine serum (HyClone), sodium bicarbon-
ate, 100 μg/ml streptomycin and 100 U/ml penicillin
(HyClone) at 37°C, in a humidified 5% CO2 atmosphere.
Antibodies and reagents
PTS2 and PT were purchased from J&K Chemical LTD.
Adriamycin (ADM) was purchased from Hisun (Zhejiang
Hisun Pharceutical Co., LTD). Cisplatin (DDP) was
purchased from QiLu (QiLu Pharmaceutical Co., LTD.).
MTT, Hoechst33258, DAPI and propidium iodide (PI)
were from Sigma (Sigma Chemical Co., St Louis, MO).
Antibodies to caspase-3, PARP, CyclinD1, CyclinE1 and
caspase-9 were purchased from Cell Signaling Technology
(Beverly, MA). Antibodies to p21 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). All chemicals
and drugs were prepared in PBS immediately before use.
Western blotting
Western blotting was performed as described previously
[13]. Cells were washed twice with ice-cold PBS (pH 7.4)Figure 1 Chemical structure of PTS2.and lysed in a lysis buffer containing 50 mM Tris–
HCl (pH 8.0), 150 mM NaCl, 0.5 mM dithiothreitol,
1 mM EDTA, 1% NP-40, 10% (v/v) glycerol, 50 μg/ml
phenylmethylsulfonyl fluoride, 2 μg/ml aprotinin, 1 μg/ml
leupeptin, 1 μg/ml pepstatin and 1 mM Na3VO4. After in-
cubation on ice for 20 min, lysates were centrifuged at
15,000× g for 10 min at 4°C and the supernatant was trans-
ferred to a clean microfuge tube. Equal amounts of the sol-
uble protein were denatured in SDS, electrophoresed on
SDS-polyacrylamide gel, and transferred to a PVDF mem-
brane. Horseradish peroxidase (HRP)-conjugated goat
anti-rabbit IgG antibodies were used against respect-
ive primary antibodies. Proteins were visualized using
Lumi-Light Western Blotting Substrate (Roche Molecular
Biochemicals). The total density of the protein bands
was calculated using the Scion Image software program
(Scion Corp., Frederick, MD).
Cell proliferation assay
Cells were seeded into 96-well plates at 5 × 103 cells
per well 24 h before treatment. After treatment with
different drugs, cell proliferation was determined using
MTT (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay. Briefly, 15 μl (5 mg/ml) MTT solution
was added to each well, and incubated at 37°C for
4 h, after which the MTT solution was removed and
200 μl of dimethylsulfoxide (DMSO) added to dis-
solve the crystals. Absorbance of each well was mea-
sured at 570 nm using an ELx 800 Universal Microplate
Reader (Bio-Tek, Inc.) according to manufacturer’s
instructions.
Trypan blue assay
Cells were seeded in 6-well culture plates. After 24 h,
culture medium containing 2.5 μg/ml of PTS2 was
added to the wells. Cells were harvested at indicated
times and washed with PBS, followed by centrifugation
at 2500 g for 5 min. The cell pellet was then re-
suspended in 1 ml of fresh culture medium; 10 μl of the
cell suspension was stained with an equal volume of try-
pan blue (Sigma, Germany) and incubated for 2 min at
37°C. The total number of viable cells was estimated
using a hemocytometer chamber.
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A staining solution of Hoechst33258 was prepared im-
mediately before use. After drug treatment, cells were
collected and fixed in acetic acid/methanol (1:3) solution
for 5 min at 4°C, washed 3 times with PBS, and then in-
cubated with Hoechst33258 (50 ng /ml) for 5 min and
washed 3 times with PBS. Cells were then assessed for
Hoechst fluorescence in a Nikon Optiphot fluorescence
microscope (magnification: ×400).
DAPI staining
Cells for 4′-6-diamidino-2-phenylindole (DAPI) staining
underwent the same PTS2 treatment as those stained
with Hoechst33258. Collected cells were fixed with
acetic acid/methanol (1:3) solution for 10 min at room
temperature and then incubated in DAPI (1 μg/ml) for
5 min. After being washed 3 times with PBS, cells were
examined using a Nikon Optiphot fluorescence micro-
scope (magnification: ×400).
Cell cycle analysis
Cell cycle distribution was analyzed by flow cytometry.
Control and treated cells were harvested, washed twice
with PBS, and fixed in 70% ethanol overnight at −20°C.
Fixed cells were washed twice with PBS, incubated with
1 ml of PBS containing 50 μg/ml propidium iodide,
100 μg/ml RNase A and 0.1% Triton X-100 for 30 min
at 37°C. Stained cells were analyzed using a FAScan laser
flow cytometer (Becton Dickinson) and ModFit LT cell
cycle analysis software (Verity Software).
Apoptosis assay
Apoptosis was determined using Annexin V-FITC/ PI
double staining. After treatment, floating and adherent
cells were collected, washed twice with PBS (pH 7.4),
resuspended in 150 μl of Annexin-binding buffer and in-
cubated with 0.4 μl of Annexin V-FITC. After 20 min in-
cubation in the dark at room temperature, 150 μl of
Annexin-binding buffer with 3 μl of PI (50 μg/ml) was
added just before flow cytometry. Data were analyzed by
flow cytometry using the FACSCalibur and Cell Quest
software (Becton Dickinson).
Animals and solid tumor models
All experiments followed the recommendations of the
Chinese Experimental Animals Administration Legislation,
as approved by the Science and Technology Department
of Jiangsu Province. Male ICR mice (6 weeks old, 18–20 g)
purchased from Shanghai Laboratory Animal Center,
Chinese Academy Sciences, were kept in groups of five
animals per cage in a temperature-controlled room at
20 ± 2°C. They were fed a standard pellet diet and
water ad libitum. As described in [4], two groups of
40 animals each were transplanted subcutaneouslywith hepatoma 22 (H22) tumor cells (5 × 106 cells/ml) in
0.2 ml PBS into their right groins. At 24 h after tumor in-
oculation, each set of 40 mice was randomly divided into
4 groups (10 mice per group) and injected intraperitone-
ally with PTS2 (0.25 or 2.5 mg/kg/day), DDP (25 mg/kg/
day) or 0.2 ml 0.9% saline for a further 10 days. On day
11, all the animals were killed, and the tumors were dis-
sected and weighed. Tumor growth inhibition was calcu-
lated using the formula:% inhibition = 100 × ([C −T]/C),
where C is the average tumor weight of the control group
and T is the average tumor weight of each treated group.
Statistics
Statistical analysis used SPSS 12.0 (SPSS, Chicago, IL,
USA). Results are expressed as means ± S.D. Differences
between means were determined by one-way ANOVA,
followed by Student–Newman–Keuls tests for multiple
comparisons and Student’s t test for other data. P < 0.05
was considered statistically significant.
Results
PTS2 decreases cancer cell viability
To assess effects of PTS2 on cancer cell growth or pro-
liferation, 4 cancer cell lines, including KB, 231, U937
and K562, were assayed using MTT. After 36 h treat-
ment with various concentrations of PTS2, cell viability
was determined for all 4 cell lines. PTS2 (0.25–5 μg/ml)
was found to decrease cell viability in a dose-dependent
manner (Figure 2A). The effect of PTS2 on cell prolifer-
ation was also examined. Results showed that PTS2 sig-
nificantly decreased cell numbers in all 4 cancer cell
lines compared with controls, as assessed using trypan
blue (Figure 2B). These data indicate that PTS2 can de-
crease cell viability or proliferation within a suitable con-
centration range.
PTS2 induces cell cycle arrest in cancer cells
Cell proliferation is well correlated to regulation of cell
cycle progression. A common mechanism for chemo-
therapeutic drugs is blocking passage through the G1
phase of the cell cycle [14]. We therefore investigated
whether PTS2 can cause G1 cell cycle arrest in treated
cancer cells (Figure 3). Cells exposed to PTS2 at 2.5 μg/ml
for 24 h showed a marked increase in the percentage in
G1 phase, and concomitant decreases in S phase and G2
phase populations, compared with vehicle-treated controls
(Figure 3A).
As p21WAF1/Cip1 (p21) inhibits the cell cycle through
its interaction with cyclin–CDK complexes [15], and is
induced by p53 in response to DNA damage resulting in
CDK inhibition and G1 growth arrest [16]. We further
tested the effect of PTS2 on endogenous p53, p21,
CyclinD1 and CyclinE1 expression in the four cancer cell
lines. After cells were treated with PTS2 (2.5 μg/ml) for
Figure 2 Effects of PTS2 treatment on cancer cells viability.
(A) Four cancer cell lines were treated with indicated doses of PTS2
for 36 h. Cell viability was determined by MTT assay. Untreated cells
were expressed as 100%. Data are means ± S.D. from 3 independent
experiments. *P < 0.05; **P < 0.01; ***P < 0.001 compared with
untreated controls. (B) Cancer cells were incubated with 2.5 μg/ml
of PTS2, harvested at indicated times, and counted. Results show cell
numbers increase over time. Data are means ± S.D. from 3
independent experiments.
Fan et al. BMC Pharmacology and Toxicology 2013, 14:54 Page 4 of 8
http://www.biomedcentral.com/2050-6511/14/5424 h, PTS2 induced p21 accumulation in all cells as shown
by Western blot (Figure 3B). CyclinD1 and CyclinE1
expressions were downregulated. These results were in ac-
cordance with the cell cycle experiment and previous re-
ports [17,18], and suggest that PTS2-induced G1 arrest in
cancer cells could be mediated via modulation of p53,
p21, CyclinD1 and CyclinE1 levels.
PTS2 induces cancer cell apoptosis
Morphology alteration and chromatin condensation are
two indicators of cell apoptosis. To verify whether the
growth inhibitory effect of PTS2 was due to apoptosis,
KB, 231, U937 and K562 cells were treated with PTS2 at
2.5 μg/ml for 36 h, and then observed under a light
microscope or under a fluorescence microscope after
Hoechst33258 and DAPI staining. We found the PTS2-
treated cells were shrunken, with irregular fragments and
apoptotic bodies, in contrast to control cells (Figure 4A).
The typical apoptosis appearance, including condensedand dispersed or fragmented blue fluorescent particles
was observed in PTS2-treated cells compared with control
cells (Figure 4B, C), which suggests that PTS2 induces
apoptosis in these types of cancer cells obviously.
PTS2 induced cleavage of caspase-9, caspase-3 and PARP
Caspase family members, including caspase-9 and
caspase-3, as well as downstream substrates such as PARP,
are crucial mediators of the apoptotic process. To see
whether PTS2-induced cell death involved activation of
caspases and PARP, we analyzed cleavage of caspase-9,
caspase-3 and PARP in PTS2-treated cancer cells. Cells
were incubated with 2.5 μg/ml of PTS2 for 36 h. As
expected, Western blot results showed that caspase-9,
caspase-3 and PARP were cleaved (Figure 5). Activation of
caspases and PARP thereby confirmed apoptosis. This
suggests that cleavage of caspase-9, caspase-3 and PARP
are involved in PTS2-induced cancer cell apoptosis.
PTS2 is more effective to induce cancer cell apoptosis
against DDP, ADM or PT
Adriamycin (ADM) and cisplatin (DDP) are widely used
cancer drugs. To further evaluate the efficacy of PTS2 in
decreasing cancer cell viability, we compared its effects
on KB cells to those of ADM and DDP. KB cells were
exposed to 2.5 μg/ml of PTS2, ADM or DDP and
assayed with MTT. At 3–36 h after treatment, PTS2 also
showed faster results than did ADM or DDP (Figure 6A).
In the dose range of 0.25–5.0 μg/ml, PTS2 was more
effective in inhibiting cell viability than was ADM or
DDP, although PT, the precursor of PTS2, exerted no ob-
vious effect (Figure 6B). Flow cytometry analysis showed
2.5 μg/ml of PTS2 to be more effective in killing KB cell
than PT and DDP (Figure 6C). These results strongly sug-
gest that PTS2 can induce cancer cell death at least as effi-
ciently as current anti-tumor drugs.
PTS2 inhibits tumor growth
To see effects of PTS2 on murine solid tumors, hepa-
toma 22 (H22) cells (5 × 106 cells/ml) were transplanted
subcutaneously into the right groins of mice; 24 h after
tumor implantation, the mice were injected intraperito-
neally with PTS2, DDP or saline and observed for
10 days. PTS2 at 2.5 mg/kg/day reduced the weight of
H22 tumors; DDP had a similar effect at 25 mg/kg/day
(Figure 7A). The tumor growth inhibition rate of PTS2
(2.5 mg/kg/day) was more effective than DDP (25 mg/
kg/day) (Figure 7B). Moreover, the body weight increase
of the PTS2-treated mice was greater than that of the
DDP-treated mice (data not shown).
Discussion
PTS2, a compound related to pyridinethione, has been
used as a bactericide, pesticide and fungicide for a long
Figure 3 PTS2 induces cell cycle arrest in cancer cells. (A) Cancer cells were incubated with PTS2 (2.5 μg/ml) for 24 h, harvested and stained with
propidium iodide (PI). Nuclei fluorescence was measured. Percentages of cells in each cell cycle phase are also shown. Results are representative of 3
independent experiments. (B) Cells were incubated with PTS2 (2.5 μg/ml) for 24 h, and then harvested. Western blot was performed using antibodies to
p53, p21, CyclinD1, CyclinE1 and GAPDH. Results represent three independent experiments.
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toxicity on HeLa cells and reduced the weight of S180 and
H22 tumors [4]. The goal of the present study was to ex-
plore the cytotoxicity of PTS2 in other cancer cell lines
and assess its potential broad-spectrum antitumor activity.
We found PTS2 induced cell death in four cancer celllines in vitro, and decreased viability in these cell lines in a
dose-dependent manner (Figure 2). At a dose of 2.5 μg/
ml, PTS2 induced apoptosis in various cancer cell lines,
as detected by morphological and fluorescence analysis
(Figure 4), thus raising the possibility that capsaicin might
be a potential chemopreventive or therapeutic agent.
Figure 4 Treatment with PTS2 induces apoptosis in cancer
cells. All 4 cancer cell lines were treated with PTS2 (2.5 μg/ml)
for 36 h, along with untreated controls. Apoptotic nuclear
fragmentation bodies, condensed and dispersed or fragmented
particle were stained with blue fluorescence by Hoechst33258
(50 ng/ml) (B) and DAPI (1 μg/ml) (C). Cell morphology (A) was
observed in cells treated with PTS2 compared with control cells,
using fluorescence microscopy (magnification: × 400).
Figure 5 Effects of PTS2 treatment on caspase-9, caspase-3 and
PARP. Cancer cells were treated with 2.5 μg/ml of PTS2 for 36 h,
and then harvested. Western blot was used to determine proteolytic
cleavage of caspase-9, caspase-3 and PARP. GAPDH was used as
internal control. Results represent 3 independent experiments.
Figure 6 Comparison of effects of PTS2, PT, DDP and ADM on
KB cell viability. (A) PTS2, PT, DDP and ADM (2.5 μg/ml) were
added to KB cells, and assayed using MTT to determine cell viability
after incubation for the indicated times. (B) In KB cells exposed to
the indicated amounts of PTS2, PT, DDP and ADM for 36 h, cell
viability was assayed using MTT. Data are means ± S.D. from 3
independent experiments. **P < 0.01; ***P < 0.001 compared with
untreated controls. (C) KB cells were treated with 2.5 μg/ml of PTS2,
PT, and DDP for 36 h, stained with Annexin V/PI, and examined with
flow cytometry. Data are means ± S.D. ***P < 0.001, compared with
viability of untreated cells. ###P < 0.001, compared with viability of
PTS2-treated cells. Results are representative of 3 independent
experiments.
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cancer cell growth through disruption of cell cycle pro-
gression [19]. Upon cellular stress or DNA damage,
these mechanisms induce cells to undergo either cell-
cycle arrest, activation of repair systems, or apoptotic
induction. In our present study, we showed that PTS2
evidently interferes with the cell cycle in vitro (Figure 3),
arresting cells at G1 phase, and thus leading them to
Figure 7 Inhibitory effect of PTS2 on hepatoma 22 (H22)
tumors. H22 cells (5 × 106 cells/ml) in 0.2 ml of PBS were
transplanted subcutaneously into right groins of mice; 24 h after
tumor implantation, the mice were injected intraperitoneally with
PTS2 (0.25 or 2.5 mg/kg/day; n = 20), DDP (2.5 mg/kg/day; n = 10) or
0.2 ml 0.9% saline (n = 10) for another 10 days. On day 11, all the
animals were killed and the tumors dissected out and weighed
(A). **P < 0.01 compared with controls. Tumor growth inhibition rate
was calculated (B).
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PTS2-induced cell cycle arrest in cancer cells require
further investigation. Cells treated with PTS2 appear
morphologically damaged and decreased in number
(Figure 4). PTS2’s apparent induction of G1 arrest and
subsequent apoptosis suggest that it could be the basis of
an anticancer therapy. PTS2 can also induce p53, p21 ac-
cumulation and CyclinD1 and CyclinE1 downregulation
in the four tested cancer cell lines (Figure 3B).
Caspase family members, including caspases 3 and 9,
are crucial effectors of apoptosis, and are cleaved during
apoptosis [19,20]. PARP is a substrate of caspase-3; its
cleavage can indicate caspase activation in response to
apoptotic stimulus [21,22], and generation of cleaved
caspase-3 and PARP as markers for apoptosis [23]. Inanalyzing the mechanism of PTS2-induced apoptosis, we
found PTS2 treatment induced cleavage of caspase-9,
caspase-3 and PARP in cancer cells (Figure 5), which im-
plies that activation of caspase-9, caspase-3 and PARP is
involved in PTS2-induced cell death.
Such specific knowledge of PTS2’s anticancer effects is
of great benefit in antitumor therapeutic strategy. PTS2
showed both dose and time advantages in inducing can-
cer cell death over adriamycin (an amino-glycosidic
anthracycline antibiotic) and cisplatin (a platinum com-
pound), which suggests PTS2’s potential as an anticancer
drug (Figure 6). Although both PT and its derivative,
PTS2, have antifungal activities [24], PT showed no obvi-
ous anticancer activity in this study.
Conclusions
Here, we report novel toxicity of PTS2 on various can-
cers, and show PTS2 to inhibit proliferation of four can-
cer cell lines and induce apoptosis involving activation
of caspase-9, caspase-3 and PARP. These results suggest
that PTS2 has broad-spectrum antitumor activity and
could be the basis of an anticancer drug.
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